BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23370861)

  • 1. KIR gene variability in cutaneous malignant melanoma: influence of KIR2D/HLA-C pairings on disease susceptibility and prognosis.
    Campillo JA; Legaz I; López-Álvarez MR; Bolarín JM; Las Heras B; Muro M; Minguela A; Moya-Quiles MR; Blanco-García R; Martínez-Banaclocha H; García-Alonso AM; Alvarez-López MR; Martínez-Escribano JA
    Immunogenetics; 2013 May; 65(5):333-43. PubMed ID: 23370861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Influence of HLA and KIR Genes on Malignant Melanoma Development and Progression.
    Kandilarova SM; Paschen A; Mihaylova A; Ivanova M; Schadendorf D; Naumova E
    Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):73-81. PubMed ID: 28083606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Large spectrum of HLA-C recognition by killer Ig-like receptor (KIR)2DL2 and KIR2DL3 and restricted C1 SPECIFICITY of KIR2DS2: dominant impact of KIR2DL2/KIR2DS2 on KIR2D NK cell repertoire formation.
    David G; Djaoud Z; Willem C; Legrand N; Rettman P; Gagne K; Cesbron A; Retière C
    J Immunol; 2013 Nov; 191(9):4778-88. PubMed ID: 24078689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant association of KIR2DL3-HLA-C1 combination with cerebral malaria and implications for co-evolution of KIR and HLA.
    Hirayasu K; Ohashi J; Kashiwase K; Hananantachai H; Naka I; Ogawa A; Takanashi M; Satake M; Nakajima K; Parham P; Arase H; Tokunaga K; Patarapotikul J; Yabe T
    PLoS Pathog; 2012; 8(3):e1002565. PubMed ID: 22412373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals.
    Naumova E; Mihaylova A; Stoitchkov K; Ivanova M; Quin L; Toneva M
    Cancer Immunol Immunother; 2005 Feb; 54(2):172-8. PubMed ID: 15248031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant association of the KIR2DL3/HLA-C1 genotype with susceptibility to Crohn's disease.
    Díaz-Peña R; Vidal-Castiñeira JR; Moro-García MA; Alonso-Arias R; Castro-Santos P
    Hum Immunol; 2016 Jan; 77(1):104-109. PubMed ID: 26542067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for natural killer cell-mediated protection from metastasis formation in uveal melanoma patients.
    Maat W; van der Slik AR; Verhoeven DH; Alizadeh BZ; Ly LV; Verduijn W; Luyten GP; Mulder A; van Hall T; Koning F; Jager MJ; van Bergen J
    Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2888-95. PubMed ID: 19234348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of killer cell immunoglobulin-like receptor gene 2DL1 and its HLA-C2 ligand with family history of cancer in oral squamous cell carcinoma.
    Dutta A; Saikia N; Phookan J; Baruah MN; Baruah S
    Immunogenetics; 2014 Aug; 66(7-8):439-48. PubMed ID: 24818561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation at positively selected positions in the binding site for HLA-C shows that KIR2DL1 is a more refined but less adaptable NK cell receptor than KIR2DL3.
    Hilton HG; Vago L; Older Aguilar AM; Moesta AK; Graef T; Abi-Rached L; Norman PJ; Guethlein LA; Fleischhauer K; Parham P
    J Immunol; 2012 Aug; 189(3):1418-30. PubMed ID: 22772445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Killer immunoglobulin receptor genes and their HLA-C ligand are associated with Type 1 diabetes in an Eastern Indian population.
    Sanjeevi S; Sun C; Kanungo A; Sanjeevi CB
    Diabet Med; 2016 Jan; 33(1):91-6. PubMed ID: 26031759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility to Crohn's disease is mediated by KIR2DL2/KIR2DL3 heterozygosity and the HLA-C ligand.
    Hollenbach JA; Ladner MB; Saeteurn K; Taylor KD; Mei L; Haritunians T; McGovern DP; Erlich HA; Rotter JI; Trachtenberg EA
    Immunogenetics; 2009 Oct; 61(10):663-71. PubMed ID: 19789864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KIR2DL3 and the KIR ligand groups HLA-A-Bw4 and HLA-C2 predict the outcome of hepatitis B virus infection.
    Di Bona D; Aiello A; Colomba C; Bilancia M; Accardi G; Rubino R; Giannitrapani L; Tuttolomondo A; Cascio A; Caiaffa MF; Rizzo S; Di Lorenzo G; Candore G; Duro G; Macchia L; Montalto G; Caruso C;
    J Viral Hepat; 2017 Sep; 24(9):768-775. PubMed ID: 28211154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory KIR and specific HLA-C gene combinations confer susceptibility to or protection against chronic hepatitis B.
    Gao X; Jiao Y; Wang L; Liu X; Sun W; Cui B; Chen Z; Zhao Y
    Clin Immunol; 2010 Oct; 137(1):139-46. PubMed ID: 20643584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA class I and class II frequencies in patients with cutaneous malignant melanoma from southeastern Spain: the role of HLA-C in disease prognosis.
    Campillo JA; Martínez-Escribano JA; Muro M; Moya-Quiles R; Marín LA; Montes-Ares O; Guerra N; Sánchez-Pedreño P; Frías JF; Lozano JA; García-Alonso AM; Alvarez-López MR
    Immunogenetics; 2006 Jan; 57(12):926-33. PubMed ID: 16365741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of HLA-Cw, KIR2D genetic variations in 2 Chinese populations].
    Cai JH; Tian W; Li LX; Wang F; Sun KZ; Zeng QR; Guo SS; Cao Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Jun; 25(3):343-7. PubMed ID: 18543232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural killer cell receptor variants and chronic hepatitis B virus infection in the Vietnamese population.
    Auer ED; Tong HV; Amorim LM; Malheiros D; Hoan NX; Issler HC; Petzl-Erler ML; Beltrame MH; Boldt ABW; Toan NL; Song LH; Velavan TP; Augusto DG
    Int J Infect Dis; 2020 Jul; 96():541-547. PubMed ID: 32422377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Killer Ig-like receptor (KIR) genotype and HLA ligand combinations in ulcerative colitis susceptibility.
    Jones DC; Edgar RS; Ahmad T; Cummings JR; Jewell DP; Trowsdale J; Young NT
    Genes Immun; 2006 Oct; 7(7):576-82. PubMed ID: 16929347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Killer immunoglobulin-like receptor locus polymorphisms in multiple sclerosis.
    Jelcić I; Hsu KC; Kakalacheva K; Breiden P; Dupont B; Uhrberg M; Martin R; Münz C; Lünemann JD
    Mult Scler; 2012 Jul; 18(7):951-8. PubMed ID: 22185807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-evolution of KIR2DL3 with HLA-C in a human population retaining minimal essential diversity of KIR and HLA class I ligands.
    Gendzekhadze K; Norman PJ; Abi-Rached L; Graef T; Moesta AK; Layrisse Z; Parham P
    Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18692-7. PubMed ID: 19837691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with epithelial ovarian cancer.
    Giebel S; Boratyn-Nowicka A; Karabon L; Jedynak A; Pamula-Pilat J; Tecza K; Kula D; Kowal M; Frydecka I; Grzybowska E
    Hum Immunol; 2014 Jun; 75(6):508-13. PubMed ID: 24755350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.